Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations

MOUNTAIN VIEW, Calif., May 29 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that Anthony Clarke, PhD, has joined the company as Vice President, International Development Operations. He will have primary responsibilities in the development and execution...

Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd.

MOUNTAIN VIEW, Calif., May 19 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that Jeffrey S. Williams has rejoined the company in a part-time position as President, Alexza Singapore Pte. Ltd., a wholly owned subsidiary of Alexza. Mr. Williams will have ...

Carlos A. Parra Joins Alexza Pharmaceuticals as Vice President, Quality

MOUNTAIN VIEW, Calif., May 15 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that Carlos A. Parra has joined the company as Vice President, Quality. He will have responsibilities in the development and execution of quality program strategies for Alexza'...

Alexza to Announce 2009 Second Quarter Financial Results and Update Its Clinical Pipeline Status on Wednesday, August 5, 2009

...IN VIEW, Calif., July 27 /PRNewswire-FirstCall/ -- alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced ...ber for the replay of the call is 21321723. alexza Pharmaceuticals is a pharmaceutical company focuse...on in schizophrenic or bipolar disorder patients. alexza has completed and announced positive results from ...

Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002

...IN VIEW, Calif., June 15 /PRNewswire-FirstCall/ -- alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced ... purchase of Symphony Allegro, which is subject to alexza stockholder approval, is projected to close in Q3 2009. alexza and Symphony Capital Partners, LP have negotiated ...

Alexza's Corporate Presentation to be Webcast at the Piper Jaffray Fourth Annual Europe Conference

...IN VIEW, Calif., June 11 /PRNewswire-FirstCall/ -- alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced ...zhtml?ticker=ALXA&item_id=2262656 or at the alexza Investor Relations tab at www.alexza.com . ...e replay will be archived for 14 days. About alexza Pharmaceuticals, Inc. ...

Alexza's Corporate Presentation to be Webcast at the Eighth Annual JMP Securities Research Conference

...N VIEW, Calif., May 11 /PRNewswire-FirstCall/ -- alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced ... http://www.wsw.com/webcast/jmp8/alxa or at the alexza Investor Relations tab at www.alexza.com . ...e replay will be archived for 14 days. About alexza Pharmaceuticals, Inc. ...

Alexza Reports 2008 Year-End Financial Results and Updates Clinical Pipeline Status

...N VIEW, Calif., March 10 /PRNewswire-FirstCall/ -- alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) reported t... $45.1 million in the comparable periods in 2007. alexza had consolidated cash, cash equivalents and market...n currently anticipated. On January 1, 2006, alexza adopted FAS 123R and reports employee share-based ...

Alexza's Corporate Presentation to be Webcast at the Cowen & Company 29th Annual Health Care Conference

...IN VIEW, Calif., March 9 /PRNewswire-FirstCall/ -- alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced ...e replay will be archived for 14 days. About alexza Pharmaceuticals, Inc. alexza Pharmaceuticals is an emerging specialty pharmaceu...

Alexza to Announce 2008 Financial Results and Update Its Clinical Pipeline on Tuesday, March 10, 2009

...IN VIEW, Calif., March 6 /PRNewswire-FirstCall/ -- alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced ...umber for the replay of the call is 94291130. alexza Pharmaceuticals is an emerging specialty pharmaceu...on in schizophrenic or bipolar disorder patients. alexza has completed and announced positive results from ...

Alexza in Medical Technology

Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration

CHADDS FORD, Pa., Jan. 29 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP ) announced today that by mutual agreement it has concluded its research collaboration with Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) to develop an inhaled fentanyl product for the treatment of breakthrou...

Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status

...TAIN VIEW, Calif., May 7 /PRNewswire-FirstCall/ -- alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) reported t...f $18.4 million in the comparable period in 2008. alexza had consolidated cash, cash equivalents and market...opment Update - AZ-004 ( Staccato loxapine). alexza is developing AZ-004 for the acute treatment of ag...

Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches

..., a product development partnership formed between alexza and Symphony Capital, LLC. The AZ-104 Phase...mptoms of migraine headache," said Thomas B. King, alexza President and CEO. "We believe the potential valu...at least two groups of potential patients for whom alexza believes that AZ-104 could be effective and safe i...

Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial

..., a product development partnership formed between alexza and Symphony Capital, LLC. "Alexza initiat...secondary endpoints," said James V. Cassella, PhD, alexza Senior Vice President, Research and Development. ... to acutely treat agitation," said Thomas B. King, alexza President and CEO. "We are very encouraged with t...

Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients

...secondary endpoints," said James V. Cassella, PhD, alexza Senior Vice President, Research and Development. "...te to treat acute agitation," said Thomas B. King, alexza President and CEO. "We are very encouraged with th...on in early 2010." Conference Call Information alexza will host a conference call later today, Tuesday, ...

Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates

...d $21.2 million in the comparable periods in 2007. alexza had consolidated cash, cash equivalents and market...re-based compensation costs. On January 1, 2006, alexza adopted FAS 123R and reports employee share-based ...evelopment Update -- AZ-004 (Staccato loxapine). alexza is developing AZ-004 for the treatment of acute ag...

Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)

..., a product development partnership formed between alexza and Symphony Capital, LLC. "We are excited to be...before the end of September," said Thomas B. King, alexza President and CEO. "This year is a transitional ye... AZ-004 study enrolling bipolar disorder patients. alexza projects that this second Phase 3 clinical trial w...

Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting

...patients with schizophrenia or bipolar disorder. alexza Pharmaceuticals is an emerging specialty pharmaceu...h greater ease, patient comfort and convenience. alexza has six product candidates in clinical development...ation, including this and past press releases from alexza is available online at http://www.alexza.com . ...

Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation

...n patients with schizophrenia or bipolar disorder. alexza believes the novel, non-invasive nature and rapid ...r original schedule," said James V. Cassella, PhD, alexza Senior Vice President, Research and Development an...tential sales and marketing," said Thomas B. King, alexza President and CEO. "We also remain on schedule to ...

Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder

...n patients with schizophrenia or bipolar disorder. alexza will host an investor conference call to discuss t...Senior Vice President, Research and Development at alexza and chairman of the Symphony Allegro Development B...tack. About Symphony Allegro In December 2006, alexza entered into a collaboration with Symphony Capital...

Alexza in Biological Technology

Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering

MOUNTAIN VIEW, Calif., July 9 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that Christopher Kurtz has joined the company as Vice President, Global Supply Chain and Sustainment Engineering. He will have primary responsibilities in the development and e...

Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing

MOUNTAIN VIEW, Calif., Feb. 27 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that Michael J. Simms has joined the company as Senior Vice President, Operations and Manufacturing. Mr. Simms was most recently Senior Vice President, Manufacturing Operation...

Alexza to Announce 2009 First Quarter Financial Results and Update Its Clinical Pipeline Status on Thursday, May 7, 2009

...N VIEW, Calif., April 30 /PRNewswire-FirstCall/ -- alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced ...umber for the replay of the call is 16474219. alexza Pharmaceuticals is a pharmaceutical company focuse...on in schizophrenic or bipolar disorder patients. alexza has completed and announced positive results from ...

Alexza's Corporate Presentation to be Webcast at the Future Leaders in the Biotech Industry Conference

...N VIEW, Calif., March 23 /PRNewswire-FirstCall/ -- alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced ...e replay will be archived for 14 days. About alexza Pharmaceuticals, Inc. alexza Pharmaceuticals is an emerging specialty pharmaceu...

Alexza's Corporate Presentation to be Webcast at the 11th Annual BIO CEO & Investor Conference

...replay will be archived for 14 days. About alexza Pharmaceuticals, Inc. alexza Pharmaceuticals is an emerging specialty pharmaceu...on in schizophrenic or bipolar disorder patients. alexza has completed and announced positive results from ...

Alexza Consolidates Operations to Focus Resources on AZ-004 (Staccato(R) Loxapine) for Acute Agitation

...3% of the Company's total workforce. In addition, alexza and Endo Pharmaceuticals, Inc. have agreed to mutu...additional resources to AZ-003 during 2009. alexza expects to reduce its expenses by approximately $2...ed to fiscal year 2009. As of September 30, 2008, alexza had $78.0 million in cash and investments. As a r...

Anesiva Announces Appointment of William Houghton, M.D. as Senior Vice President and Chief Medical Officer

... Anesiva, he was chief medical officer of Eleos, Inc., a private company. From 2005 to 2007 he was vice president, clinical and regulatory affairs for alexza Pharmaceuticals, Inc., where he was responsible for the development and conduct of clinical trials for a novel Fentanyl formulation, among others. Fro...

Alexza Pharmaceuticals Announces Upcoming Webcasts and Conference Participation

...e company's participation and that Thomas B. King, alexza President and CEO, will present at the following i...accessed via the Investor Relations section of the alexza website, at http://www.alexza.com . A replay of t...d the replay will be archived for 14 days. About alexza Pharmaceuticals ...

Alexza to Announce 2008 Second Quarter Financial Results and Update Its Clinical Pipeline on Wednesday, August 6, 2008

...allers. The reference number to enter the replay of the call is 47372481. alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on ...s administration, but with greater ease, patient comfort and convenience. alexza has six product candidates in clinical development. Alexza's lead program, ...

Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates

...of $10.9 million in the comparable period in 2007. alexza had consolidated cash, cash equivalents and market...re-based compensation costs. On January 1, 2006, alexza adopted FAS 123R and reports employee share-based ...velopment Update -- AZ-004 (Staccato loxapine). alexza is developing AZ-004 for the treatment of acu...